TY - JOUR T1 - Third doses of COVID-19 vaccines reduce infection and transmission of SARS-CoV-2 and could prevent future surges in some populations: a modeling study JF - medRxiv DO - 10.1101/2021.10.25.21265500 SP - 2021.10.25.21265500 AU - Billy J. Gardner AU - A. Marm Kilpatrick Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/11/29/2021.10.25.21265500.abstract N2 - Background Vaccines have greatly reduced the impact of COVID-19, but vaccine protection against milder disease and infection have waned significantly, especially for the Delta variant (B.1.617.2). A third booster dose of two-dose vaccines could restore protection but the benefit of boosting immunity in younger healthy individuals and the resultant effects on transmission have not been quantified.Methods We develop relationships between neutralizing antibody titers and vaccine protection against both infection and transmission. We combine these relationships with data on waning and boosting of neutralizing antibody titers to examine the impact of third doses of Pfizer-BioNtech and Moderna vaccines on infection and transmission and the impact on the pathogen effective reproductive number Rt.Findings Waning reduced protection of the Pfizer-BioNtech vaccine against all infections from 80.0% (95% CI: 77% to 83%) to 60.4% (95% CI: 53% to 67%), and for the Moderna vaccine from 83.8 (95% CI: 80 to 87%) to 65.9% (95% CI: 61-71%). A third dose increased neutralizing antibody titers 25.9-fold relative to waned levels for the Pfizer-BioNtech vaccine and 13-fold relative to waned levels for the Moderna vaccine. This increased protection against infection to 87.2% (95% CI: 83% to 91%) and 86.3% (95% CI: 82% to 90%) for Pfizer and Moderna, respectively. Increased protection against infection and transmission from third doses reduced Rt by 28% to 74% depending on vaccine coverage and previous infection and reduced Rt below 1 when vaccination coverage was high or contact rates were well below pre-pandemic levels.Interpretation A third vaccine dose could substantially reduce transmission of SARS-CoV-2 and prevent future surges, with the impact increasing with vaccine coverage and contact rates among individuals. Reducing transmission would reduce infection in both unvaccinated individuals and breakthrough infections in vaccinated individuals.Funding California Department of Health, National Science FoundationCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the California Department of Health and the National Science Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript https://github.com/marmkilpatrick/Vaccine-boosters ER -